Amid large scale vaccination in the country, the US government announced it will procure 1.7 million doses of antiviral treatment molnupiravir for <a href="https://www.wionews.com/world/singapores-death-toll-from-covid-19-tops-casualties-in-sars-outbreak-390385">coronavirus</a> treatment from Merck.

Watch:

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/united-states-pfizer-vaccine-trials-underway-for-kids-aged-5-to-11-years-390133/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The procurement will be made pending emergency use authorization (EUA) or approval from the US Food and Drug Administration (FDA).

Molnupiravir treatment is being evaluated in the&nbsp;ongoing Phase 3 trial for its potential to reduce the risk of hospitalization or death, the US government release said.

The treatment is designed to induce viral genome copying errors to prevent the <a href="https://www.wionews.com/science/fatigue-ptsd-depression-and-more-heres-how-to-fight-post-covid-problems-390332">virus</a> from replicating in the human body. The company said it was pleased to collaborate with the US government while aiming to produce 10 million courses by the end of this year.

It is a drug to be taken over a five-day period. The phase 3 trial of the drug is set to begin involving 1,850 people with results expected later this year.

The drug is usually given to patients early before the virus turns severe.

According to the government, molnupiravir has proved effective against other viruses namely influenza, Ebola,&nbsp;Venezuelan Equine and Encephalitis virus in lab studies although it hasn't been approved by the FDA.

The health department said it is part of the <a href="https://www.wionews.com/world/it-shows-paranoid-delusion-of-egoism-says-china-on-us-innovation-bill-390379">Biden</a> administration’s approach to develop new COVID-19 treatments.

Amid large scale vaccination in the country, the US government announced it will procure 1.7 million doses of antiviral treatment molnupiravir for coronavirus treatment from Merck.

Amid large scale vaccination in the country, the US government announced it will procure 1.7 million doses of antiviral treatment molnupiravir for coronavirus treatment from Merck. Watch: The procurement will be made pending emergency use authorization (EUA) or approval from the US Food and Drug Administration (FDA). Molnupiravir treatment is being evaluated in the ongoing Phase 3 trial for its potential to reduce the risk of hospitalization or death, the US government release said. The treatment is designed to induce viral genome copying errors to prevent the virus from replicating in the human body. The company said it was pleased to collaborate with the US government while aiming to produce 10 million courses by the end of this year. It is a drug to be taken over a five-day period. The phase 3 trial of the drug is set to begin involving 1,850 people with results expected later this year. The drug is usually given to patients early before the virus turns severe. According to the government, molnupiravir has proved effective against other viruses namely influenza, Ebola, Venezuelan Equine and Encephalitis virus in lab studies although it hasn't been approved by the FDA. The health department said it is part of the Biden administration’s approach to develop new COVID-19 treatments.

US to procure 1.7 million courses of molnupiravir coronavirus pills

Indian firm Bharat Biotech's homegrown Covid vaccine has shown an interim efficacy of 81 per cent in late-stage clinical trials, the company has said.

The trials involved 25,800 subjects in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement on Wednesday.

"Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today's results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants," Bharat Biotech Chairman and Managing Director Krishna Ella said.

Covaxin demonstrates high clinical efficacy trend against Covid-19 but also significant immunogenicity against the rapidly emerging variants.

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), and Oxford-AstraZeneca's Covishield are the two vaccines that are being administered in the country.

Indian firm Bharat Biotech's homegrown Covid vaccine has shown an interim efficacy of 81 per cent in late-stage clinical trials, the company has said. The trials involved 25,800 subjects in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement on Wednesday.

Indian firm Bharat Biotech's homegrown Covid vaccine has shown an interim efficacy of 81 per cent in late-stage clinical trials, the company has said. The trials involved 25,800 subjects in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement on Wednesday. "Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today's results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants," Bharat Biotech Chairman and Managing Director Krishna Ella said. Covaxin demonstrates high clinical efficacy trend against Covid-19 but also significant immunogenicity against the rapidly emerging variants. Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), and Oxford-AstraZeneca's Covishield are the two vaccines that are being administered in the country.

Bharat Biotech's Covaxin found 81% efficient in Phase 3 trials

The Gamaleya research centre expects the efficacy rate of its vaccine against the coronavirus, Sputnik V, to further increase, the centre's deputy director of science, Denis Logunov, said Monday. 
 
<a href="https://www.wionews.com/world/four-trial-volunteers-who-got-pfizers-covid-19-vaccine-developed-bells-palsy-348547">Also read: Four trial volunteers who got Pfizer's COVID-19 vaccine developed Bell's palsy</a> 
 
According to the institute, Sputnik V vaccine against COVID-19 is likely to provide up to two years of immunity from COVID-19, compared to the four or five months immunity that may be achieved by using the vaccine produced by Pfizer and BioNTech. 
 
"Concerning our vaccine and the platform it was created on, the Ebola vaccine, there is experimental evidence that using this platform, using similar preparation methods, provides protection for two years at least, maybe more. It is difficult to say how long the Pfizer vaccine will give immunity, but based on the general findings from such vaccines, one must think that the period of protection will be no more than four to five months, although this requires experimental data," Alexander Gintsburg, the head of Russia's Gamaleya research institute, said. 
 
<a href="https://www.wionews.com/world/new-variant-of-coronavirus-identified-in-uk-london-in-tier-3-lockdown-349785">Also read: New variant of coronavirus identified in UK; London in Tier 3 lockdown</a> 
 
According to Logunov, the overall efficacy rate of 91.4 per cent was calculated for people who received both doses of vaccine. There are 21 days between the two injections, so the calculations took into account the cases starting from 21 days and on. 
 
<a href="https://www.wionews.com/world/us-administers-first-coronavirus-vaccine-donald-trump-congratulates-americans-349779">Also read: US administers first coronavirus vaccine; Donald Trump congratulates Americans</a> 
 
"Obviously, it showed high efficiency, but since we were counting from 21 days onward and including the cases, we also hope that if we increase the vaccination period to 28, 35, 42 days, the efficacy numbers may grow," Logunov told a briefing.

"The data analysis at the third and final control point of the Sputnik V vaccine clinical trials confirmed its efficacy of the of over 90 per cent. Clinical trials have proven this in the three consecutive statistically important points described in the trial protocol," remarked RDIF Chief Executive Officer Kirill Dmitriev.

The joint statement read that the analysis of the Sputnik V vaccine efficacy at the final control point was carried out on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases).&nbsp;

"The ratio of the placebo group to the vaccinated group is 1 to 3," said the joint statement.

As of Monday, over 26,000 volunteers were vaccinated at 29 medical centres in Russia, as part of the ongoing clinical trials. Currently, Phase 3 trials are ongoing in countries like Belarus, the United Arab Emirates (UAE), and Venezuela, while Phase 2/3 trials are being conducted in India.

The statement mentioned that no unexpected adverse events were identified as part of the research as of now, although some of those vaccinated had short-term minor adverse events such as pain at the injection point and flu-like symptoms, including fever, weakness, fatigue, and headache.

"The new data on the efficacy of the Gamaleya Center vaccine is extremely encouraging. Today it has become obvious to everyone that the end of the pandemic is possible only after the mass vaccination of the entire global population. In this regard, ensuring equal access to effective and safe vaccines, including the Sputnik V, for people in every country should be the goal of foreign regulatory bodies and international organizations," said Mikhail Murashko, Minister of Health of the Russian Federation.

Russia became the first country to register the world`s first COVID-19 vaccine on August 11, Sputnik V, named after Russia`s first satellite. 
 
(With inputs from agencies)

The Gamaleya research centre expects the efficacy rate of its vaccine against the coronavirus, Sputnik V, to further increase, the centre's deputy director of science, Denis Logunov, said Monday.

The Gamaleya research centre expects the efficacy rate of its vaccine against the coronavirus, Sputnik V, to further increase, the centre's deputy director of science, Denis Logunov, said Monday. Also read: Four trial volunteers who got Pfizer's COVID-19 vaccine developed Bell's palsy According to the institute, Sputnik V vaccine against COVID-19 is likely to provide up to two years of immunity from COVID-19, compared to the four or five months immunity that may be achieved by using the vaccine produced by Pfizer and BioNTech. "Concerning our vaccine and the platform it was created on, the Ebola vaccine, there is experimental evidence that using this platform, using similar preparation methods, provides protection for two years at least, maybe more. It is difficult to say how long the Pfizer vaccine will give immunity, but based on the general findings from such vaccines, one must think that the period of protection will be no more than four to five months, although this requires experimental data," Alexander Gintsburg, the head of Russia's Gamaleya research institute, said. Also read: New variant of coronavirus identified in UK; London in Tier 3 lockdown According to Logunov, the overall efficacy rate of 91.4 per cent was calculated for people who received both doses of vaccine. There are 21 days between the two injections, so the calculations took into account the cases starting from 21 days and on. Also read: US administers first coronavirus vaccine; Donald Trump congratulates Americans "Obviously, it showed high efficiency, but since we were counting from 21 days onward and including the cases, we also hope that if we increase the vaccination period to 28, 35, 42 days, the efficacy numbers may grow," Logunov told a briefing. "The data analysis at the third and final control point of the Sputnik V vaccine clinical trials confirmed its efficacy of the of over 90 per cent. Clinical trials have proven this in the three consecutive statistically important points described in the trial protocol," remarked RDIF Chief Executive Officer Kirill Dmitriev. The joint statement read that the analysis of the Sputnik V vaccine efficacy at the final control point was carried out on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases). "The ratio of the placebo group to the vaccinated group is 1 to 3," said the joint statement. As of Monday, over 26,000 volunteers were vaccinated at 29 medical centres in Russia, as part of the ongoing clinical trials. Currently, Phase 3 trials are ongoing in countries like Belarus, the United Arab Emirates (UAE), and Venezuela, while Phase 2/3 trials are being conducted in India. The statement mentioned that no unexpected adverse events were identified as part of the research as of now, although some of those vaccinated had short-term minor adverse events such as pain at the injection point and flu-like symptoms, including fever, weakness, fatigue, and headache. "The new data on the efficacy of the Gamaleya Center vaccine is extremely encouraging. Today it has become obvious to everyone that the end of the pandemic is possible only after the mass vaccination of the entire global population. In this regard, ensuring equal access to effective and safe vaccines, including the Sputnik V, for people in every country should be the goal of foreign regulatory bodies and international organizations," said Mikhail Murashko, Minister of Health of the Russian Federation. Russia became the first country to register the world`s first COVID-19 vaccine on August 11, Sputnik V, named after Russia`s first satellite. (With inputs from agencies)

Developers say Sputnik V likely to give 2 years Covid-19 immunity, Pfizer 4-5 months

phase-3-trials

Phase 3 Trials, News on Phase 3 Trials, stories on Phase 3 Trials, articles on Phase 3 Trials, Phase 3 Trials stories at Wion, Phase 3 Trials news, Phase 3 Trials latest news

phase 3-trials

US to procure 1.7 million courses of molnupiravir coronavirus pills

Bharat Biotech's Covaxin found 81% efficient in Phase 3 trials

Developers say Sputnik V likely to give 2 years Covid-19 immunity, Pfizer 4-5 months